Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

NCT03737994 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03737994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03737994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
July 25, 2019
Completion date
March 17, 2026
Enrollment
10 (actual)
Sites
491

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-squamous non-small cell carcinoma, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8